ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease

OBJECTIVE: To evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD). METHODS: In this phase 2 trial, 431 patients with mild to moderate AD 50 to 80 years of age were randomized 2:1 (crenezumab:placebo). Patients received low-dose subcutaneous crenezu...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neurology
Autori principali: Cummings, Jeffrey L., Cohen, Sharon, van Dyck, Christopher H., Brody, Mark, Curtis, Craig, Cho, William, Ward, Michael, Friesenhahn, Michel, Rabe, Christina, Brunstein, Flavia, Quartino, Angelica, Honigberg, Lee A., Fuji, Reina N., Clayton, David, Mortensen, Deborah, Ho, Carole, Paul, Robert
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lippincott Williams & Wilkins 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5962917/
https://ncbi.nlm.nih.gov/pubmed/29695589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000005550
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi